NEWS

New 3 year data supports Kite ‘cure’ hopes for CAR–T
pharmaphorum
The study involved Kite’s own CAR–T candidate KTE019, which will soon be reviewed by the FDA in in patients with aggressive NHL including diffuse large B-cell lymphoma (DLBCL). Kite is chasing Novartis, which just two weeks ago received a landmark …

and more »

87 experimental therapies for glioblastoma are in the works. Some might help McCain now
STAT
Market research company Informa Pharma Intelligence counts 87 experimental therapies, from vaccines and gene therapy to monoclonal antibodies (the workhorses of precision medicine), in clinical trials for glioblastoma. Most of those won’t be approved …
Senator McCain faces uphill battle in fight against aggressive cancerYour News Now
What do We Know About Senator McCain’s Brain Tumor?550 KTSA
McCain cancerEast County Magazine

all 2,017 news articles »

Widecells’ ground-breaking stem cell insurance platform goes live in the UK
Proactive Investors UK
WideCells Group PLC’s (LON:WDC) stem cell insurance platform Cellplan has now gone live in the UK. The online facility initially will be for customers of tissue bank Biovault, but in the upcoming weeks WideCells intends to make CellPlan available to …
WideCells Group PLC CellPlan launches E-Commerce Platform in the UKDirectorsTalk Interviews

all 2 news articles »

9 Amazing Things We’ve Achieved in 2017 With Help From CRISPR
ScienceAlert
CRISPR has been used to successfully target the ‘command centre’ of cancer – the hybrid fusion genes that often trigger abnormal tumour growths. By cutting and pasting, researchers created a cancer-busting gene that actually shrunk tumours in mice …
Resistance to CRISPR gene drives may arise easilyScience News Magazine
Researchers Design, Construct Genome-Wide Sequence-Verified Arrayed CRISPR LibraryGenomeWeb
Library of CRISPR targeting sequences increases power of the gene-editing methodEurekAlert (press release)
Digital Journal –Xinhua –Genetic Engineering & Biotechnology News
all 12 news articles »

9 Amazing Things We’ve Achieved in 2017 With Help From CRISPR
ScienceAlert
CRISPR has been used to successfully target the ‘command centre’ of cancer – the hybrid fusion genes that often trigger abnormal tumour growths. By cutting and pasting, researchers created a cancer-busting gene that actually shrunk tumours in mice …
Resistance to CRISPR gene drives may arise easilyScience News Magazine
Researchers Design, Construct Genome-Wide Sequence-Verified …GenomeWeb
Library of CRISPR targeting sequences increases power of the gene …EurekAlert (press release)
Digital Journal –Xinhua –Genetic Engineering & Biotechnology News
all 12 news articles »

9 Amazing Things We’ve Achieved in 2017 With Help From CRISPR
ScienceAlert
CRISPR has been used to successfully target the ‘command centre’ of cancer – the hybrid fusion genes that often trigger abnormal tumour growths. By cutting and pasting, researchers created a cancer-busting gene that actually shrunk tumours in mice …
Resistance to CRISPR gene drives may arise easilyScience News Magazine
Researchers Design, Construct Genome-Wide Sequence-Verified Arrayed CRISPR LibraryGenomeWeb
Library of CRISPR targeting sequences increases power of the gene-editing methodEurekAlert (press release)
Technology Networks –Digital Journal –Xinhua
all 13 news articles »

9 Amazing Things We’ve Achieved in 2017 With Help From CRISPR
ScienceAlert
CRISPR has been used to successfully target the ‘command centre’ of cancer – the hybrid fusion genes that often trigger abnormal tumour growths. By cutting and pasting, researchers created a cancer-busting gene that actually shrunk tumours in mice …
Resistance to CRISPR gene drives may arise easilyScience News Magazine
Researchers Design, Construct Genome-Wide Sequence-Verified …GenomeWeb
Library of CRISPR targeting sequences increases power of the gene …EurekAlert (press release)
Xinhua –The Economist –Genetic Engineering & Biotechnology News
all 12 news articles »

SillaJen : China’s FDA Oks To Commence Phase 3 Trial For Oncolytic Immunotherapy
Nasdaq
(RTTNews.com) – SillaJen, Inc. and Lee’s Pharmaceutical Holdings Ltd. announced approval by the China Food and Drug Administration to conduct a Phase 3 clinical trial for advanced liver cancer using its oncolytic immunotherapy called Pexa-Vec (formerly …

and more »